

REMARKS

The foregoing amendments are presented to place the application in compliance with the Sequence Rules under 37 C.F.R. § 1.821-1.825.

Enclosed herewith is a substitute Sequence Listing in both paper and computer readable form as required by 37 C.F.R. § 1.821(c) and (e). Amendments directing its entry into the specification have also been incorporated herein. The content of the paper and computer readable copies are the same and no new matter has been added.

The substitute Sequence Listing corrects the errors noted in the Notice to Comply. A copy of the Notice is attached herewith as required. The substitute Sequence Listing has been run through the PTO Checker software (version 4.4.0) and no errors were found.


In view of the foregoing, it is believed that each requirement set forth in the Notice has been satisfied, and that the application is now in compliance with the Sequence Rules under 37 C.F.R. § 1.821-1.825.

On pages 1-2 of the Notice, it was indicated that additional claim fees of \$200 are required for 3 independent claims in excess of 3. This position is respectfully traversed, because the application only contains 5 independent claims (i.e., claims 1, 2, 5, 10, and 11), and not 6. Accordingly, there are only 2 extra independent claims in excess of 3. The fee for these 2 extra independent claims was appropriately paid on January 13, 2006. Therefore, no extra claim fees are required at this time.

Favorable action on the merits is respectfully requested.

Respectfully submitted,

Masahiko KURODA et al.

By: 
Jay F. Williams
Registration No. 48,036
Attorney for Applicants

JFW/akl
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
August 11, 2006

ATTACHMENTS

1. Copy of Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures; and
2. Revised Sequence Listing (CRF & Paper copy).